Palatin Technologies, Inc. · AMEX:PTN
Palatin Technologies — Investor Presentation (August 2026)
40 slides from Palatin Technologies's investor presentation, August 2026
Slide 1: Palatin Technologies Corporate Presentation August 2026
Palatin Technologies, Inc. Nasdaq: PTN CORPORATE PRESENTATION August 2026 Carl Spana, Ph.D. Stephen T. Wills, CPA/MST President & CEO CFO / COO
Slide 2: Forward Looking Statements
Forward Looking Statements The statements in this presentation that relate to future plans, events or performance are forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements involve si
Slide 3: Company Profile
Company Profile Technology platform – targeting the melanocortin system MC4R agonists therapeutics for syndromic and genetic obesity Demonstrated expertise moving programs from discovery to FDA approval Expertise in the biology and chemistry of melanocortin system (MCS) 1st company to gain FDA appro
Slide 4: Palatin Leadership
Palatin Leadership Strong team, with broad and extensive biopharma experience Stephen T. Wills, CPA/MST Carl Spana, PhD Chief Financial Officer and President and Chief Executive Officer Chief Operating Officer Co-founder with 25-plus years in drug 25-plus years in finance, operations, research, deve
Slide 5: Development Programs
Development Programs Novel ‘next generation’ MC4R selective agonists for treatment of rare neuroendocrine diseases Therapies for patients with obesity caused by an impaired leptin melanocortin-4 receptor (MC4R) pathway Focus on hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl
Slide 6: MC4R Obesity Programs
C o n MC4R Obesity Programs f MC4R pathway regulates obesity and energy management through satiety & food intake i d e n t i a l Central leptin-melanocortin pathway is a critical pathway that regulates feeding and body weight to maintain energy homoeostasis 6 Sweeney, P et.al. Nature Reviews Endocri
Slide 7: Rare MC4R Pathway Diseases
Rare MC4R Pathway Diseases • Hypothalamic Obesity (HO) • Prader-Willi Syndrome (PWS) • Bardet-Biedl Syndrome (BBS)
Slide 8: Hypothalamic Obesity (HO)
Hypothalamic Obesity (HO) A rare, acquired form of obesity following injury to the hypothalamus or congenital Acquired HO • Craniopharyngioma are brain tumors that develop near the hypothalamus and pituitary gland. • Treatments include tumor resection surgery, radiation or both. • Treatment damages
Slide 9: Prader-Willi Syndrome (PWS)
Prader-Willi Syndrome (PWS) A complex, multi-system disorder • PWS by deletion ~70% of cases o Part of the chromosome 15 that was inherited from the person’s father is missing, or deleted, in this critical region. • PWS by maternal uniparental disomy (UPD) ~30% of cases o Occurs when an individual i
Slide 10: Bardet-Biedl Syndrome (BBS)
Bardet-Biedl Syndrome (BBS) Affects multiple organ systems, significant morbidity and reduced quality of life • A rare genetic disorder caused by mutations in genes involved in cilia function (“ciliopathy”) • Associated with severe early-onset obesity driven by hyperphagia and impaired satiety o Pat
Slide 11: Rare MC4R Pathway Diseases (Treatment of Obesity w/ MC4R Agonist)
Rare MC4R Pathway Diseases (Treatment of Obesity w/ MC4R Agonist) Prevalence of HO, PWS, and BBS – a severe, life-long burden for patients Acquired HO PWS**** BBS***** 5,000 – 10,000 ~20,000 4,000 – 5,000 Est. U.S. prevalence* Est. U.S. prevalence Est. U.S. prevalence 5,000 – 10,000 ~400,000 4,000 –
Slide 12: Melanocortin-4 Receptor (MC4R) Obesity Programs
Melanocortin-4 Receptor (MC4R) Obesity Programs • Novel “Next Generation” MC4R Selective Agonists o Peptides - Once Weekly Dosing o Oral Small Molecules
Slide 13: Novel "Next Generation" MC4R Selective Agonists
Novel "Next Generation" MC4R Selective Agonists Strategy / Focus Developing next-generation, best-in-class MC4R therapies designed to improve potency, tolerability, and long-term usability through enhanced receptor selectivity and reduced off-target effects 13
Slide 14: Novel "Next Generation" MC4R Selective Peptide Agonists
Novel "Next Generation" MC4R Selective Peptide Agonists Legacy challenges of MC4R peptide agonists have been solved Current Therapy Challenges Palatin Achieved Solutions Palatin’s compounds with high potency coupled with structural elements, Injection Frequency extend drug residency time (≥ 1 week)
Slide 15: Novel "Next Generation" MC4R Selective Peptide Agonists
Novel "Next Generation" MC4R Selective Peptide Agonists First series / Second series First series of ‘next generation’ MC4R peptide agonists for obesity: • Palatin studies in MC4R knock-out model confirm weight loss is dependent on a functional MC4R • Next-generation class lead development candidate
Slide 16: Palatin compounds reduce / (potentially) eliminate MC1R agonism
Novel "Next Generation" Selective MC4R Peptide Agonists Palatin compounds reduce / (potentially) eliminate MC1R agonism Agonist MC1R EC50 (Emax) MC4R EC50 (Emax) MC4R Selectivitya Bremelanotide 0.23 nM (91.8%) 5.01 nM (91.0%) 0.05 Setmelanotide 0.4 nM (106%) 0.66 nM (98.8%) 0.61 PL8905 30.2 nM (78.5
Slide 17: PL8905 weight loss studies in DIO and MC4R knockout mice
Novel "Next Generation" MC4R Selective Peptide Agonists In vivo PL8905 weight loss studies in diet-induced obese (DIO) and MC4R knockout (KO) mice Change in Body Weight Body Weight in Wild Type DIO Mice and MC4R-Knockout Mice Change in body weight 6 Body Weight Change (%) 4 Vehicle PL-8905 0.3mg/kg
Slide 18: Structural changes result in excellent PK & once weekly exposure
Novel "Next Generation" MC4R Selective Peptide Agonists Structural changes result in excellent PK & once / weekly injection exposure / efficacy PL10265 Plasma Concentrations in Male SD Rats following 100000 a Single Subcutaneous Dose of 3 mg/kg 10000 Rat 1 Plasma Concentration (ng/mL) Rat 2 1000 Rat
Slide 19: Long-acting once weekly administration SC peptides
Novel "Next Generation“ MC4R Selective Peptide Agonists Activities – long-acting once weekly administration SC peptides Highly selective MC4R agonists designed to avoid hyperpigmentation, and enabling once-weekly injection into one compound accomplished • Multiple candidates being profiled for recep
Slide 20: MC4R selective oral small molecule program
Melanocortin-4 Receptor (MC4R) Obesity Programs MC4R selective oral small molecule program for treatment of rare MC4R pathway diseases Current Therapy Challenges Palatin Achieved Solutions Palatin identified small molecules show excellent preclinical oral Injection Frequency bioavailability Palatin
Slide 21: Understanding what is required for success
MC4R Obesity Programs for Treatment of Rare MC4R Pathway Diseases Novel “next generation” MC4R selective agonists: understanding what is required for success Historically, MC4R small molecule programs have failed due to a lack of understanding the receptor biology and the structure/function relation
Slide 22: Ideal PK profile for an obesity treatment
MC4R Obesity Programs for Treatment of Rare MC4R Pathway Diseases Ideal PK profile for an obesity treatment (PK consistency across mouse, rat, dog) • Oral administration • Protein binding facilitates efficacious levels without surpassing them • PL7737 compound does not have a high transient Cmax hel
Slide 23: PL7737 reduces body weight in DIO mice
MC4R Obesity Programs for Treatment of Rare MC4R Pathway Diseases MC4R selective oral small molecule PL7737 @ 3, 10 and 30mg/kg reduces body weight in DIO mice PL7737 is a novel MC4R selective oral small molecule agonist. Body Weight Change in DIO mice % Change from Day 0 Vehicle subtracted 2 study
Slide 24: Solving MC1R selectivity/activity
"Next Generation“ MC4R Selective Oral Small Molecule Agonists Solving MC1R selectivity/activity Palatin advances in understanding ligand/receptor interactions has led to the ability to significantly reduce and potentially eliminate MC1R selectivity/activity. • Learnings from our peptide program have
Slide 25: Next steps and development timeline overview
Melanocortin-4 Receptor (MC4R) Obesity Programs Next steps and development timeline overview Treating rare MC4R pathway diseases: primary focus on Hypothalamic Obesity (HO), Prader-Willi Syndrome (PWS) and Bardet-Biedl Syndrome (BBS) MC4R selective agonists • Long-acting peptide (weekly SC administr
Slide 26: MC4R Agonist Generalized Obesity Management
MC4R Agonist Generalized Obesity Management • Bremelanotide MC4R agonist Phase 1b clinical weight loss study in general obese subjects • Co-administration of Bremelanotide MC4R & Tirzepatide (GLP-1/GIP) o Bremelanotide (BMT) MC4R Agonist ✓ FDA Approved (Vyleesi® for Female HSDD)
Slide 27: Bremelanotide Phase 1b weight loss study
C o n MC4R Agonist Generalized Obesity Management f Bremelanotide MC4R agonist obesity Phase 1b clinical weight loss study in general obese subjects i d e n t i 2-Week Study a l • General obese subjects: BMI ~35 o Bremelanotide: n=27 o Vehicle: n=26 • Weight loss: o Placebo -0.7kg; o Bremelanotide:
Slide 28: GLP-1/GIP agonist + MC4R agonist co-administration data
MC4R Agonist Generalized Obesity Management GLP-1/GIP agonist + MC4R agonist: co-administration clinical data* • No prospective studies have been done with combination pharmacotherapy • Previously published combination of setmelanotide plus 2.5mg of tirzepatide for obesity in BBS • 2 patients lost 2
Slide 29: BMT-801 signal detection study objectives
MC4R Agonist Generalized Obesity Management BMT-801 Phase 2 signal detection study objectives Co-Administration GLP1/GIP Agonist Tirzepatide (2.5mg Weekly) + MC4R Agonist Bremelanotide (1.25mg Daily) Main Research Questions • Does co-administration result in increased weight loss? • Does MC4R agonis
Slide 30: BMT-801 signal detection study design
MC4R Agonist Generalized Obesity Management BMT-801 Phase 2 signal detection study Co-Administration GLP1/GIP Agonist Tirzepatide & MC4R Agonist Bremelanotide Study Design: Randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of the addition of an MC4R agonist (BMT)
Slide 31: Co-administration additive effect – primary analysis
MC4R Agonist Generalized Obesity Management Co-administration additive effect – primary analysis Analysis for Additive Effect Percent of Subjects with ≥4% Reduction in Percent Weight Loss at End of Study 60 Group 1 Group 2 Group 3 Group 4 Group 1: Tirzepatide (2.5 mg SC) weekly/BMT (1.25 mg SC) dail
Slide 32: Effect of co-administration on increased weight loss
MC4R Agonist Generalized Obesity Management Effect of co-administration on increased weight loss Weekly Change in Percent Body Weight (%) by Group 0 -0.5 • Comparison of Group 4 to -1 Group 3 during Treatment Period 2 demonstrates a Percent Change in % Weight -1.5 weight loss maintenance -2 effect -
Slide 33: Value of the study results and next steps
MC4R Agonist Generalized Obesity Management BMT-801 MC4R/GLP-1-GIP co-administration detection study Value of the study results and next steps Confirmation that MC4R treatment with GLP-1/GIP can BMT-801 Study be additive without increasing safety and tolerability issues Support to perform co- Provid
Slide 34: Financial Snapshot / Cap Table; Spin-Out / Out-License Programs
Financial Snapshot / Cap Table Spin-Out / Out-License Programs Development Programs Overview Milestones Recap
Slide 35: Financial Snapshot / Cap Table
Financial Snapshot / Cap Table Financial Highlights as of March 31, 2026 Cash and Cash Equivalents $10.2 million Other Receivables $2.2 million Expected to be received during QE 6/30/2026 No debt Summary Capitalization as of March 31, 2026 Common Shares and Equivalent Common Stock 1.8 million shares
Slide 36: Spin-Out / Out-License Programs
Spin-Out / Out-License Programs Product/Indication R&D Phase 1 Phase 2 Phase 3 NDA Status/Next Steps Ocular Phase 3 MELODY-1 completed - positive data PL9643 MCR Agonist Phase 3 Melody-2 & -3 potential initiation 2026 Dry eye disease (DED) Sublicense Agreement with Altanispac Labs Research Collabora
Slide 37: Research Collaboration / License Agreement with Boehringer Ingelheim
Development Programs Overview Research Collaboration / License Agreement with Boehringer Ingelheim August 2025 • Potential to develop first-in-class proprietary melanocortin receptor €280M treatment for patients with retinal diseases Potential milestones (~$328M) + tiered royalties • Collaboration s
Slide 38: Development Programs Overview: Pipeline
Development Programs Overview Pipeline Obesity Development Programs Preclinical Phase 1 Phase 2 Phase 3 NDA Status/Next Steps Once-Weekly Peptide MC4R Agonists IND enabling – CMC activities ongoing Multiple obesity indications with focus on IND filing 4Q 2026 HO, PWS, BBS diseases Phase 1 SAD/MAD da
Slide 39: Milestones Recap
Milestones Recap Melanocortin System Development Programs Status Obesity - MC4R Selective Agonists – Treatment of Rare MC4R Pathway Diseases (Primary Focus HO, PWS, BBS) Phase 2 BMT-801 Clinical Study Bremelanotide + GLP-1 (proof-of-concept study only) – Positive Topline Data Reported Completed Once
Slide 40: Thank You
Thank You & PALATIN
Palatin Technologies — Investor Presentation (August 2026) on 6ix